ADRB3 and neoplasm: Results showed that lymphocytes silenced for β3-AR, among the β-AR subtypes, partially lost their ability to induce PD-L1 expression on N2A tumor cells compared to control condition (Fig. 5E and Supplementary Fig. 1D).